T. Simon

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study

C. Hawkey, L. Laine, H. Badsha, 2003, Gut.

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

J. Bolognese, H. Quan, I. Bjarnason, 2000, Gut.

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study

C. Hawkey, L. Laine, H. Badsha, 2003, Gut.